Floatz logo

Entacapone

Autonomic Nervous System Disorder

Daniel ClaassenSmall moleculePhase 1/2Active
CCC
54/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
40/ 100
Competitive Position
95/ 100

Competitive context

10 Active assets in the Autonomic Nervous System Disorder cohort.

Asset / SponsorPhaseRating
Droxidopa
Vanderbilt University Medical Center
Phase 1/2CCC
carbidopa
Daniel Claassen
Phase 1/2CCC
Midodrine
Vanderbilt University Medical Center
Phase 1CCC
Fezolinetant
Shehzad Basaria, M.D.
Phase 2CCC
FDOPA
Daniel Claassen
Phase 1CC

View all 12 →

Same molecule, other indications

Entacapone is also rated in:

Parkinson diseaseDormant
BBB
Indicative ·
74 / 100
View asset →
Neurodegenerative DiseasesDormant
B
Indicative ·
62 / 100
View asset →
Central Nervous System DiseasesDormant
B
Indicative ·
62 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →